Eagle's Eye View: Your Weekly CV Update From ACC.org

In this week's View, Dr. Eagle looks at a collaborative analysis of three randomized trials that investigated inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy. He then covers the 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction. Finally, Dr. Eagle explores ACTIVE-AF, a randomized controlled trial on exercise and physical activity program in patients with atrial fibrillation.   Subscribe to Eagle's Eye View  

 In this week's View, Dr. Eagle discusses the value of the balloon pulmonary angioplasty procedure for patients with chronic thromboembolic pulmonary hypertension. He then reviews the sub analysis of the HOST EXAM trial assessing the benefit of aspirin versus clopidogrel as a maintenance strategy after coronary stenting.    Finally, Dr. Eagle explores the BIOVASC trial weighing in on immediate versus staged complete revascularization in patients presenting with acute coronary syndrome and multivessel coronary disease.    Subscribe to Eagle's Eye View  

In this week's View, Dr. Deepak Bhatt sits in for Dr. Eagle and discusses heart failure following anti-inflammatory medications in patients with type 2 diabetes mellitus, then looks at the results of the ARCHITECT Study concerning alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia.    Finally, Dr. Bhatt explores a state-of-the-art review of the benefits of exercise in cardiovascular diseases, from mechanisms to clinical implementation.   Subscribe to Eagle's Eye View  

In this week's View, Dr. Deepak Bhatt discusses a three-decade exploration from the Aortic Institute at Yale University on the rate of the unoperated ascending thoracic aortic aneurysm. He then looks at the final study report of andexanet alfa for major bleeding with factor Xa inhibitors. Finally, Dr. Bhatt explores subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort.  Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle discusses implantable defibrillator system shock function, mortality, and cause of death after magnetic resonance imaging. He then explores the association of preoperative medical consultation with a reduction in adverse postoperative outcomes and use of processes of care.   Finally, Dr. Eagle explores a comprehensive analysis of a multicenter registry that examined the prognostic implications of discordant low-gradient severe aortic stenosis.  Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle discusses the incidence of cardiac arrest during sports among women versus men, then looks at a scientific statement from the American Heart Association on atrial fibrillation occurring during acute hospitalization. Finally, Dr. Eagle explores the results reported in the RACING Trial that addressed the use of moderate-intensity statins with ezetimibe vs. high-intensity statins in patients with diabetes and atherosclerotic cardiovascular disease.  Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle discusses a prespecified analysis of the NUDGE-FLU trial that reported on the effectiveness of electronic nudges on influenza vaccination rate in older adults with cardiovascular disease, then looks at a comparison of the ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis. Finally, Dr. Eagle explores a long-term study of pregnancy complications and long-term mortality in a diverse cohort. Subscribe to Eagle's Eye View 

Dr. Deepak Bhatt reviews the Day 3 late-breaking science from ACC.23, including FREEDOM COVID ANTICOAG (0:52), STELLAR Phase III (1:49), and PULSED AF (2:49). The ACC is providing coverage of the hottest ACC.23 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #ACC23 to join the conversation.  Subscribe to Eagle's Eye View 

Drs. Michael Gibson, Suzanne Baron and Deepak Bhatt review the Day 2 late-breaking science from ACC.23, including BIOVASC (0:39), UK MINI MITRAL (2:12), and BETTER CARE HF (4:15). The ACC is providing coverage of the hottest ACC.23 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #ACC23 to join the conversation.    Subscribe to Eagle's Eye View  

Drs. Michael Gibson, Rasha Al-Lamee and Javed Butler review the Day 1 late-breaking science from ACC.23, including CLEAR OUTCOMES (0:41), TRILUMINATE (2:35) and STOP CA (5:25).    The ACC is providing coverage of the hottest ACC.23 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page  and follow the ACC on social media using #ACC23 to join the conversation.     

In this week's View, Dr. Eagle discusses Lp(a) as a main driver for the risk of ASCVD, MI, and aortic valve stenosis independent of CRP. This article is timely as we continue to attempt to lower the risks with ongoing trials currently working on relevant therapeutic options for lowering Lp(a).   Then Dr. Eagle looks at women with CHD and mild PH who appear to have better pregnancy outcomes as compared with those with moderate-to-severe PH.   Finally, Dr. Eagle explores the PARTNER Trials and its insights concerning cardiac damage and quality of life after Aortic Valve Replacement.   We are looking forward to continuing to engage you during ACC.23 (March 4-6) in this formidable time of education! Check back for further updates!  Subscribe to Eagle's Eye View

Cardiovascular professionals are coming together for ACC.23 in New Orleans, March 4-6, to learn the latest practice-changing breakthrough research and trials results from around the world. In this View episode, guest host Deepak Bhatt MD, MPH, FACC, offers a preview of some of the hottest trials at ACC.23.   Kicking us off on Day 1, Saturday, March 4, we will hear the positive outcomes from the CLEAR OUTCOMES trial and the favorable data for structural heart disease coming out of the TRILUMINATE trial.  Day 2, Sunday, March 5, can't be missed! Among the many presentations: UK MINI MITRAL weighs the minimally invasive approach versus conventional sternotomy for mitral valve repair surgery and the RENOVATE COMPLEX PCI trial that examines intravascular imaging-guided versus angiography-guided procedural optimization in complex percutaneous coronary intervention – a subject of particular interest to interventionalists. And that's just the beginning: the 5-year final results from the COAPT trial are in; the 3-year outcomes from the EVOLUT low risk trial sound positive and continue to be in favor of TAVR; the BIOVASC trial data will be released, and it's likely the findings will continue to be in favor of complete revascularization strategies in patients presenting with acute coronary syndromes and multivessel coronary disease.  On Monday, the last day of the conference, Dr. Valentin Fuster will present the FREEDOM COVID ANTICOAG trial, discussing anticoagulation strategies in non-critically ill hospitalized COVID patients. Next up, the STELLAR trial, a study of sotatercept in combination with background therapy for the treatment of pulmonary arterial hypertension, will be presented. And finally, the findings of the collaborative analysis of participants in the three major trials are also scheduled: the PROMINENT, REDUCE-IT, STRENGTH trials.  Be sure to check back on Eagle's Eye View throughout the meeting for further updates.  Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle discusses a clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions on renal denervation in the management of hypertension in adults, then looks at the risk of surgical mitral valve repair for primary mitral regurgitation. Finally, Dr. Eagle explores an observational study that examines primary prevention of acute cardiovascular events by influenza vaccination.  Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle discusses the recent expert panel statement on positron emission tomography (PET) for assessment of coronary microvascular dysfunction, then looks at the impact of transcatheter mitral valve repair availability on the volume and outcomes of surgical repair. Finally, Dr. Eagle explores the 2023 ACC/AHA/SCAI Advanced Training Statement on Interventional Cardiology.  Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle discusses P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions, then looks at practical approaches to genetic screening in cardiomyopathies. Finally, Dr. Eagle explores long-term outcomes of perioperative myocardial infarction or injury after non-cardiac surgery.   Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle discusses the ACC Expert Consensus Documents on comprehensive multidisciplinary care for the patient with cardiac amyloidosis, then looks at findings from the SPRINT Trial on the effect of intensive blood pressure control on troponin and natriuretic peptide levels. Finally, Dr. Eagle explores early extracorporeal CPR for refractory out-of-hospital cardiac arrest compared to traditional CPR.   Subscribe to Eagle's Eye View  

In this week's View, Dr. Eagle discusses recurrent venous thromboembolism and bleeding with extended anticoagulation and the VTE-PREDICT risk score, then looks at infective endocarditis after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores aspirin and low-molecular-weight heparin for thromboprophylaxis after a fracture. Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle discusses the treatment of radiation-induced aortic stenosis, then looks at PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection. Finally, Dr. Eagle explores myocardial injury on CMR in patients with COVID-19 and suspected cardiac involvement. Subscribe to Eagle's Eye View https://twitter.com/keaglemd https://twitter.com/accintouch?lang=en

In this week's View, Dr. Eagle discuses heart failure drug treatment - inertia, titration and discontinuation as analyzed in EVOLUTION HF, a multinational observational study, then looks at Non-Obstructive Coronary Arteries (INOCA), and insights gained from the ISCHEMIA Trial. Finally, Dr. Eagle explores findings regarding exercise volume versus intensity and the progression of coronary atherosclerosis in middle-aged and older athletes from the MARC-2 Study.  Subscribe to Eagle's Eye View  

Top Clinical Trials It was another great year for trial coverage on ACC.org! There were almost 140,000 unique views of the top 10 trials and top 10 trial updates for the year. Treatment of heart failure and of hypertrophic cardiomyopathy were hot topics. In addition to covering new trials, we updated prior trials with any related significant presentations or publications. We have added new features for our learners to make clear what is updated compared with the prior version of a clinical trial summary. Hopefully, this change allows quicker reading of these trial synopses. Interestingly, some of the trial updates had more views than de novo trial coverage. We have also started providing visual abstracts for some of the key trials at the major meetings. We are striving to make ACC.org a very user-friendly educational portal. On behalf of the ACC.org staff, Happy Holidays and a joyous New Year to you all! Deepak L. Bhatt, MD, MPH, FACC Senior Associate Editor, Clinical Trials and News, ACC.org Subscribe to Eagle's Eye View

In 2022 with much of the care landscape returning to more normalcy after the COVID-19 pandemic eased, we saw the most visited journal scan content on ACC.org once again focused on common areas of cardiovascular practice and areas with advances in therapy.  ACC.org is a home for condensed, digestible content particularly around important summary documents like the guidelines and consensus statements.  In 2022, we saw release of new heart failure guidelines, new guidelines for the evaluation of cardiovascular disorders prior to non-cardiac surgery and also for pulmonary hypertension, a summary statement on the use of aspirin for primary prevention, and a state-of-the-art summary on rhythm control for atrial fibrillation.  The ACC looks forward to an exciting 2023 and the opportunity to continue to partner with you in the provision of “state of the art” information for your practice! — Kim A. Eagle, MD, MACC Subscribe to Eagle's Eye View

In this interview, Dhanunjaya "DJ" Lakkireddy MBBS, FACC and Alison L. Bailey MD FACC discuss the Top Takeaways from 2022: Electrophysiology. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this week's View, Dr. Eagle discusses a systematic review and meta-analysis of aortic stenosis progression, then looks at a meta-analysis of randomized trials on the use of dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk. Finally, Dr. Eagle explores the three-year results of the SUCCOUR trial that investigated cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy' Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle discusses medical masks versus N95 respirators for preventing COVID-19 among health care workers, then looks at an excellent metanalysis of antioxidant micronutrient supplementation to reduce cardiovascular risk. Finally, Dr. Eagle explores the prognosis of myocarditis developing after mRNA COVID-19 vaccination compared to viral myocarditis. Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle discusses trends in the use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, then looks at a collaborative meta-analysis of large placebo-controlled trials that examines the impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes. Finally, Dr. Eagle explores insights from the PEGASUS-TIMI 54 trial regarding patient selection for long-term secondary prevention with ticagrelor. Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle discuses hypertension management in patients with cardiovascular comorbidities, then looks at a patient-level analysis of Phase III trials that examines Inclisiran and cardiovascular events. Finally, Dr. Eagle explores the STROKESTOP study on the cost-effectiveness of population screening for atrial fibrillation. Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle discusses the most important aspects of the new ACC AHA Guidelines for the diagnosis and management of aortic disease. Subscribe to Eagle's Eye View  

Drs. Deepak Bhatt, Kim Eagle and Payal Kohli review Day 3 late-breaking science from AHA 2022, including ENHANCE-AF (0:32), PRECSION (2:40), BrightHTN (4:08), and SPYRAL HTN-ON (6:41). The ACC is providing coverage of the hottest AHA 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #AHA22 to join the conversation.

Drs. Deepak Bhatt, Kim Eagle and Payal Kohli review Day 2 late-breaking science from AHA 2022, including ECMO-CS (0:42), RESPECT-EPA (2:22), ISCHEMIA-EXTENDed (5:45) and EMPA-KIDNEY (7:39). The ACC is providing coverage of the hottest AHA 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #AHA22 to join the conversation.

In this special AHA episode of Eagle's Eye View, Drs. Deepak Bhatt, Kim Eagle and Payal Kohli discuss highlights from Day 1 of the AHA 2022 late-breaking science, including TRANSFORM-HF, DCP, PROMINENT, and IRONMAN. The ACC is providing coverage of the hottest AHA 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #AHA22 to join the conversation.

In this week's View, Dr. Eagle discusses a secondary analysis of the REPRISE III randomized clinical trial on long-term outcomes of transcatheter aortic valve replacement with the Lotus valve vs the CoreValve/EvolutR, then looks at iron deficiency and cardiovascular disease. Finally, Dr. Eagle explores the association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation. Subscribe to Eagle's Eye View

In this episode, guest host Deepak Bhatt, MD, MPH, FACC, offers a preview of some of the most important and clinically transformative studies being presented at the AHA 2022 Conference, November 5-7. Day One includes two major studies on diuretics: primary results from the TRANSFORM HF Trial, examining the comparative effectiveness of torsemide versus furosemide in heart failure, and from the DCP Trial on chlorthalidone compared to hydrochlorothiazide for the prevention of cardiovascular events in patients with hypertension. Day One also includes a presentation on PROMINENT, a randomized trial of pemafibrate for triglyceride reduction in the prevention of cardiovascular disease. Day Two includes a major and important presentation of data from EMPA-KIDNEY, examining empagliflozin and cardiovascular outcomes in patients with chronic kidney disease. QUARTET USA, a randomized control trial investigating the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension is also on the agenda. The primary results of ECMO-CS, a multicenter randomized trial on extracorporeal membrane oxygenation in the therapy of cardiogenic shock will be presented as well.  The third and final day opens with BEST-CLI Trial, looking at the best endovascular versus best surgical therapy for patients with chronic limb-threatening ischemia, followed by a primary analysis from the RAPID Trial, focusing on self-administered etripamil for termination of spontaneous paroxysmal supraventricular tachycardia, followed by results from the Phase 2 NOVA Trial, examining the efficacy and safety of botulinum toxin type A for the prevention of postoperative atrial fibrillation in cardiac surgery patients.  There will also be a group of presentations on the treatment of persistent hypertension,  beginning with the top-line results from FRESH, looking at the first-in-class aminopeptidase-A inhibitor firibastat in treatment-resistant hypertension, followed by data from, PRECISION, a randomized controlled study including a withdrawal phase, investigating the sustained blood pressure-lowering effect with the dual endothelin receptor antagonist aprocitentan in resistant hypertension, followed in turn by the results from BrightHTN, a Phase 2 randomized double-blind placebo-controlled trial evaluating the efficacy and safety of baxdrostat in patients with treatment-resistant hypertension, and concluding with information on the 6-month primary results of SPYRAL HTN-ON, investigating the effect of radiofrequency renal denervation on blood pressure in the presence of antihypertensive drugs.   AHA 2022 promises to be a rich and rewarding experience for those who can attend in person or participate virtually. Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle discusses the European Atherosclerosis Society's consensus statement on lipoprotein(a) [Lp(a)] in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, then looks at CHD screening in kidney and liver transplant candidates.

In this week's View, Dr. Eagle discusses the TIME Study, a prospective, randomized, open-labe,l blinded-endpoint clinical trial exploring cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives, then looks at phenotyping the hypertensive heart. Finally, Dr. Eagle takes a look at a multinational study on programmed ventricular stimulation as an additional primary prevention risk stratification tool in arrhythmogenic right ventricular cardiomyopathy. Subscribe to Eagle's Eye View

In this week's View, Dr. Deepak Bhatt sits in for Dr. Eagle to discuss TIMING, a registry-based randomized controlled noninferiority study that examines early versus delayed non–Vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation, then looks at the Fingersture study on plaque histology and myocardial disease in sudden coronary death. Finally, Dr. Bhatt takes a look at a recent paper on evolving management concepts for left main coronary disease. Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle discusses the Fitbit Heart Study that examines the detection of atrial fibrillation in a large population using wearable devices, then looks at the long-term effects of P2Y12 inhibitor monotherapy after percutaneous coronary intervention. Finally, Dr. Eagle examines a scientific statement on sex differences in arterial hypertension from the ESC Council on Hypertension, the European Association of Preventive Cardiology, the Association of Cardiovascular Nursing and Allied Professions, the ESC Council for Cardiology Practice, and the ESC Working Group on Cardiovascular Pharmacotherapy. Subscribe to Eagle's Eye View

In this week's View, Dr. Eagle discusses a scientific statement from the American Heart Association on the management of patients at risk for and with left ventricular thrombus, then looks at the nationwide CONCEPTION study concerning pregnancy and the onset of chronic hypertension. Finally, Dr. Eagle examines the risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years of age in France. Subscribe to Eagle's Eye View

In this special episode of Eagle's Eye View, Drs. Deepak Bhatt, Bina Ahmed and Roxana Mehran discuss highlights from Day 3 of the TCT 2022 late-breaking science, including PCSK9 Inhibition, FAVOR III China, and SCAAR. The ACC is providing coverage of the hottest TCT 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #TCT2022 to join the conversation.

In this special episode of Eagle's Eye View, Drs. Deepak Bhatt, Bina Ahmed and Roxana Mehran discuss highlights from Day 2 of the TCT 2022 late-breaking science, including RADIANCE II, SYMPLICTY HTN-3, pulmonary denervation, and UNIVERSAL. The ACC is providing coverage of the hottest TCT 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #TCT2022 to join the conversation.

In this special ESC Congress episode of Eagle's Eye View, Drs. Deepak Bhatt, Bina Ahmed and Roxana Mehran discuss highlights from Day 1 of the TCT 2022 late-breaking science, including PROTECTED TAVR, Amulet IDE, and CLASP IID. The ACC is providing coverage of the hottest TCT 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #TCT2022 to join the conversation.

In this week's View, Dr. Eagle discusses a multinational analysis with external cohort validation of sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland:, then looks at a comprehensive meta-analysis of five randomized controlled trials concerning SGLT-2 inhibitors in patients with heart failure. Finally, Dr. Eagle examines routine functional testing or standard care in high-risk patients after PCI.

In this episode, guest host Dr. Deepak Bhatt offers a preview of some of the most important and clinically transformative studies being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 conference taking place Sept. 16-19 in Boston, MA. The ACC is providing coverage of the hottest TCT 2022 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #TCT2022 to join the conversation.

In this week's View, Dr. Deepak Bhatt sits in for the vacationing Dr. Eagle to discuss a prespecified analysis of the DELIVER Trial that investigated the efficacy and safety of dapagliflozin according to frailty in patients with heart failure, then looks at a separate paper on the DELIVER Trial that examines dapagliflozin for heart failure according to body mass index. Finally, Dr. Bhatt examines a prospective cohort study of UK Biobank participants that looked at the association between device-measured physical activity and incident heart failure.

In this special ESC Congress episode of Eagle's Eye View, Drs. Deepak Bhatt, Payal Kohli, and Philippe Gabriel Steg discuss highlights from Day 4 of the ESC Congress 2022: late-breaking science and featured clinical research, including POISE-3, SPYRAL HTN-ON MED, EMPULSE, and FIDELITY.

In this special ESC Congress episode of Eagle's Eye View, Drs. Deepak Bhatt, Payal Kohli, and Philippe Gabriel Steg discuss highlights from Day 3 of the ESC Congress 2022: late-breaking science and featured clinical research, including INVICTUS, FACTOR XIa trials, AXIOMATIC-SSP, MOMENTUM 3, and POST-PCI.

In this special ESC Congress episode of Eagle's Eye View, Drs. Deepak Bhatt, Payal Kohli, and Philippe Gabriel Steg discuss highlights from Day 2 of the ESC Congress 2022: late-breaking science and featured clinical research, including DANCAVAS, REVIVED-BCIS2, ADVOR, ALL-HEART, and DELIVER.